- Home
- APRE vs TNON Comparison
APRE vs TNON Comparison
Compare APRE & TNON Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- APRE
- TNON
- Stock Information
- Founded
- APRE 2006
- TNON 2012
- Country
- APRE United States
- TNON United States
- Employees
- APRE N/A
- TNON N/A
- Industry
- APRE Biotechnology: Biological Products (No Diagnostic Substances)
- TNON Medical Specialities
- Sector
- APRE Health Care
- TNON Health Care
- Exchange
- APRE Nasdaq
- TNON Nasdaq
- Market Cap
- APRE 9.4M
- TNON 10.6M
- IPO Year
- APRE 2019
- TNON 2022
- Fundamental
- Price
- APRE $1.69
- TNON $1.39
- Analyst Decision
- APRE Strong Buy
- TNON Strong Buy
- Analyst Count
- APRE 1
- TNON 3
- Target Price
- APRE $20.00
- TNON $11.67
- AVG Volume (30 Days)
- APRE 60.0K
- TNON 13.6M
- Earning Date
- APRE 08-12-2025
- TNON 08-13-2025
- Dividend Yield
- APRE N/A
- TNON N/A
- EPS Growth
- APRE N/A
- TNON N/A
- EPS
- APRE N/A
- TNON N/A
- Revenue
- APRE $841,012.00
- TNON $2,947,000.00
- Revenue This Year
- APRE N/A
- TNON $39.03
- Revenue Next Year
- APRE N/A
- TNON $66.24
- P/E Ratio
- APRE N/A
- TNON N/A
- Revenue Growth
- APRE N/A
- TNON N/A
- 52 Week Low
- APRE $1.41
- TNON $0.85
- 52 Week High
- APRE $5.01
- TNON $15.79
- Technical
- Relative Strength Index (RSI)
- APRE 46.79
- TNON 56.99
- Support Level
- APRE $1.66
- TNON $1.33
- Resistance Level
- APRE $1.79
- TNON $1.74
- Average True Range (ATR)
- APRE 0.14
- TNON 0.22
- MACD
- APRE -0.01
- TNON 0.01
- Stochastic Oscillator
- APRE 38.89
- TNON 27.81
About APRE Aprea Therapeutics Inc. Common stock
Aprea Therapeutics Inc is a clinical-stage biopharmaceutical company. The group is focused on precision oncology through synthetic lethality. Its pipeline products include ATRN-119, a clinical-stage small molecule ATR inhibitor in development for solid tumor indications. APR-1051, an oral, small-molecule WEE1 inhibitor, recently entered the clinic.
About TNON Tenon Medical Inc.
Tenon Medical Inc is a medical device company that has developed a novel, minimally invasive approach to the sacroiliac joint (the SI Joint) using a single, robust, titanium implant for the treatment of the common types of SI Joint disorders that cause lower back pain. The Company is focused on three commercial opportunities; Primary SI Joint procedures, Revision procedures of failed SI Joint implants, and SI Joint fusion adjunct to a spine fusion construct. The company derives the majority of its revenue from sales of The Catamaran System to a limited number of clinicians.